(Circulation. 2004;109:III-8 III-14.)
© 2004 American Heart Association, Inc.
Atherosclerosis: Evolving Vascular Biology and Clinical Implications |
From the Institute of Clinical Chemistry and Laboratory Medicine (G.A.), Central Laboratory, Westphalian Wilhelms-University, and the Institute of Arteriosclerosis Research at the University of Münster (G.A.), Münster, Germany; and Weill Medical College of Cornell University (A.M.G.), New York, NY.
Correspondence to Prof. Dr Gerd Assmann, Institute of Arteriosclerosis Research, University of Münster, Domagkstrasse 3, D-48149 Münster, Germany. E-mail assmann{at}uni-muenster.de
A low level of high-density lipoprotein cholesterol (HDL-C) is an important risk factor for cardiovascular disease. Epidemiological and clinical studies provide evidence that HDL-C levels are linked to rates of coronary events. The cardioprotective effects of HDL-C have been attributed to its role in reverse cholesterol transport, its effects on endothelial cells, and its antioxidant activity. Although some clinical trials suggest a benefit of raising HDL-C to reduce risk, further studies are needed, and HDL-C is still not considered a primary target of therapy in the National Cholesterol Education Program guidelines. However, HDL-C should be considered as part of the patients overall profile of established risk factors in determining treatment strategies.
Key Words: atherosclerosis cardiovascular diseases cholesterol high-density lipoprotein (HDL) lipoproteins risk factors
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |